Ibaraki, Japan

Miyono Miyazaki




Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Miyono Miyazaki

Introduction

Miyono Miyazaki is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of pulmonary fibrosis. His innovative work has led to the development of a therapeutic agent that holds promise for patients suffering from this debilitating condition.

Latest Patents

Miyazaki holds a patent for a therapeutic agent for pulmonary fibrosis. This patent discloses a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid. The therapeutic agent utilizes this carrier and is accompanied by a preparation kit for its application. This invention represents a significant advancement in the treatment options available for pulmonary fibrosis.

Career Highlights

Miyazaki is currently employed at Nitto Denko Corporation, where he continues to engage in innovative research and development. His work at the company has allowed him to focus on creating solutions that address critical health issues. With a patent portfolio that includes 1 patent, he has established himself as a valuable contributor to the field.

Collaborations

Miyazaki has collaborated with several talented individuals in his field, including Yoshiro Niitsu and Rishu Takimoto. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of groundbreaking solutions.

Conclusion

Miyono Miyazaki's contributions to the field of medical science, particularly through his patent for a therapeutic agent for pulmonary fibrosis, highlight his innovative spirit and dedication to improving patient outcomes. His work at Nitto Denko Corporation and collaborations with fellow researchers further emphasize his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…